IDEAYA Biosciences, Inc. (FRA:30J)

IDEAYA Biosciences Statistics

Total Valuation

FRA:30J has a market cap or net worth of EUR 2.38 billion. The enterprise value is 1.52 billion.

Market Cap	2.38B
Enterprise Value	1.52B

Important Dates

The last earnings date was Friday, February 13, 2026.

Earnings Date	Feb 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	87.81M
Shares Outstanding	n/a
Shares Change (YoY)	+8.33%
Shares Change (QoQ)	-1.24%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	85.68M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	12.80
PB Ratio	2.74
P/TBV Ratio	2.74
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-15.66
EV / Sales	8.17
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-24.23

Financial Position

The company has a current ratio of 11.34, with a Debt / Equity ratio of 0.03.

Current Ratio	11.34
Quick Ratio	10.97
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	-0.38
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -10.92% and return on invested capital (ROIC) is -9.35%.

Return on Equity (ROE)	-10.92%
Return on Assets (ROA)	-8.92%
Return on Invested Capital (ROIC)	-9.35%
Return on Capital Employed (ROCE)	-15.17%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	1.28M
Profits Per Employee	-667,839
Employee Count	145
Asset Turnover	0.20
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +44.33% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+44.33%
50-Day Moving Average	28.87
200-Day Moving Average	23.60
Relative Strength Index (RSI)	51.45
Average Volume (20 Days)	20

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	10.17

Income Statement

In the last 12 months, FRA:30J had revenue of EUR 186.28 million and -96.84 million in losses. Loss per share was -1.09.

Revenue	186.28M
Gross Profit	-81.76M
Operating Income	-135.69M
Pretax Income	-96.84M
Net Income	-96.84M
EBITDA	-133.39M
EBIT	-135.69M
Loss Per Share	-1.09

Balance Sheet

The company has 544.57 million in cash and 23.77 million in debt, with a net cash position of 870.24 million.

Cash & Cash Equivalents	544.57M
Total Debt	23.77M
Net Cash	870.24M
Net Cash Per Share	n/a
Equity (Book Value)	871.23M
Book Value Per Share	9.92
Working Capital	517.76M

Cash Flow

In the last 12 months, operating cash flow was -60.55 million and capital expenditures -2.02 million, giving a free cash flow of -62.57 million.

Operating Cash Flow	-60.55M
Capital Expenditures	-2.02M
Free Cash Flow	-62.57M
FCF Per Share	n/a

Margins

Gross margin is -43.89%, with operating and profit margins of -72.84% and -51.99%.

Gross Margin	-43.89%
Operating Margin	-72.84%
Pretax Margin	-51.99%
Profit Margin	-51.99%
EBITDA Margin	-71.61%
EBIT Margin	-72.84%
FCF Margin	n/a

Dividends & Yields

FRA:30J does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.33%
Shareholder Yield	-8.33%
Earnings Yield	-4.06%
FCF Yield	-2.62%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:30J has an Altman Z-Score of 14.17 and a Piotroski F-Score of 3.

Altman Z-Score	14.17
Piotroski F-Score	3